|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1399 NEW YORK AVE, NW, SUITE 725 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 309071-12
|
||||||||
|
6. House ID# 384420000
|
TYPE OF REPORT | 8. Year | 2009 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Debbie Garza, Divisional Vice President - Government and Community Relations |
Date | 10/19/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S. 391/HR. 1321 the Healthy Americans Act regarding the role of pharmacy in healthcare and Title VI regarding shared responsibilities.
HR. 816 the Military Retirees Health Care Protection Act, Section 3, all provisions relating to a prohibition on increasing the cost sharing requirement under the pharmacy benefits program and a prohibition on increasing premiums under TRICARE.
S. 80 the Pharmaceutical Market Access Act of 2009, all provisions; regarding amending the federal food, drug, and cosmetic act to allow pharmacies to import qualifying drugs from certain countries into the United States.
S. 1232/S. 525/HR. 1298 the Pharmaceutical Market Access and Drug Safety Act of 2009 all provisions; regarding amending the federal food, drug, and cosmetic act to allow the importation of prescription drugs by pharmacies.
MedGuides regarding improvement needed to the Medication Guide Program no specific legislation.
Electronic Prescribing of Controlled Substances regarding the need for the DEA to publish rules that would allow for electronic prescribing of controlled substances no specific legislation.
HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug and Device Safety all provisions relating to this title on drug and device safety.
HR. 806 the TRICARE Mail Order Pharmacy Pilot Program Act, all provisions; regarding establishing a mail-order pharmacy pilot program for TRICAREe beneficiaries.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Debbie |
Garza |
|
|
|
Susie |
Schulte |
|
|
|
Heather |
Smith |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
HR 1259 the Dextromethorphan Distribution Act of 2009 all provisions of the bill; regarding amending the federal food, drug, and cosmetic act to limit the distribution and abuse of DXM.
HR. 759 the Food and Drug Administration Globalization Act of 2009 Title II Drug Safety provisions relating to country of origin labeling for drugs and devices.
HR. 1548 the Pathway for Biosimilars Act all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biotech pharmaceuticals.
S. 726/HR. 1427 the Promoting Innovation and Access to Life-Saving Medicine Act - all provisions; regarding establishing a pathway at the Food and Drug Administration for the approval of generic versions of biotech pharmaceuticals.
HR. 1815 the Consumer Product Safety Solutions Act Section 2 provision relating to lead limits and third party testing requirements, Section 3 provisions relating to phthalates prohibition, Section 4 provisions relating to clarification of testing methodologies, Section 5 provisions relating to the exclusion of certain materials from lead content limit, Section 6 provision relating to the waiver of third party testing requirements for certain component parts, Section 7 provisions relating to exemptions from tracing label requirements, Section 8- provisions relating to the general application and exemptive authority of the Consumer Product Safety Commission.
S. 882 the Drug and Device Accountability Act of 2009 Title I Ensuing the safety and quality of medical products and their components all provisions relating to this title on drug and device safety.
S. 1383 the Dextromethorphan Abuse Reduction Act of 2009 all provisions; regarding amending the Controlled Substances Act to prevent the abuse of dextromethorphan.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Debbie |
Garza |
|
|
|
Susie |
Schulte |
|
|
|
Heather |
Smith |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
HR. 1173 the Organized Retail Crime Act of 2009 all provisions, regarding amending title 18 of the United States Criminal Code to include organized retail crime and imposing requirements on on-line marketplaces to facilitate criminal investigations.
S. 470 the Combating Organized Retail Crime Act of 2009 all provisions, regarding amending the criminal code and expanding the definition of transporting and selling stolen goods from a physical or on-line marketplace.
HR. 1166 the E-Fencing Enforcement Act of 2009 all provisions, regarding amending the criminal code to impose duty on on-line marketplaces to retain contact information on high volume sellers and disclose that information when evidence is presented by law enforcement that the merchandise is stolen.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Debbie |
Garza |
|
|
|
Heather |
Smith |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S.701/HR. 2002 the Medicare Patient IVIG Access Act of 2009 Section 4, provisions relating to coverage of home administration of IVIG and reimbursement for services, supplies and equipment.
Pharmacy enhancements for consideration to the Medicare Modernization Act no specific legislation.
HR. 1765 all provisions, regarding amending the Social Security Act with respect to payment for items and services relating to the furnishing of IVIG in a patients home for the treatment of primary immune deficiency disease and to cover certain disposable pumps as durable medical equipment in place of non-disposable pumps under the Medicare program.
HR. 203 the Medicare Fraud Prevention Act of 2009 Section 4 provisions relating to the increased surety bond requirement of suppliers of durable medical equipment.
S. 956/HR 1970 the Preserve Patient Access to Reputable DMEPOS Providers Act of 2009 all provisions; regarding exempting unsanctioned State-licensed retail pharmacies from the surety bond requirement under the Medicare Program for suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS).
HR 574/S. 254 the Medicare Home Infusion Therapy Act of 2009 all provisions; regarding amending the Social Security Act to provide for the coverage of home infusion therapy under the Medicare program.
HR. 3108 the Medication Therapy Management Benefits Act of 2009, all provisions; regarding amending part D of title XVIII of the Social Security Act to promote medication therapy management under the Medicare part D prescription drug program.
HR. 3663 all provisions; regarding amending title XVIII of the Social Security Act to delay the date on which the accreditation requirement under the Medicare Program applies to suppliers of durable medical equipment that are pharmacies.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Debbie |
Garza |
|
|
|
Susie |
Schulte |
|
|
|
Heather |
Smith |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
S. 182/HR. 12 the Paycheck Fairness Act all provisions, regarding amending the Fair Labor Standards Act to provide more effective remedies to victims of discrimination in the payment of wages on the basis of sex and other purposes.
HR. 1409/S. 560 the Employee Free Choice Act all provisions, regarding amending the National Labor Relations Act to establish a system that enables employees to form, join, or assist labor organizations and to provide for mandatory injunctions for unfair labor practices during organizing efforts.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Debbie |
Garza |
|
|
|
Heather |
Smith |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Walgreens and its subsidiaries can impact efforts in health care reform with regards to access, affordability and quality.
Senate Finance Committee Health Reform Plan -Americas Healthy Future Act of 2009 regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies as related to AMPs Federal Upper Limits (FULs), regarding expanding medication therapy management (MTM) services provided by pharmacists and expanding home infusion in Medicare to cover the supplies, equipment and services.
S. 1679, the Affordable Health Choices Act - health care reform legislation introduced by Senator Edward Kennedy; regarding expanding medication therapy management (MTM) services provided by pharmacists also the establishment of a grant program to implement MTM for the treatment of chronic diseases.
HR. 3200, the Americas Affordable Health Choices Act of 2009 regarding redefining Average Manufacturers Price (AMP) to further clarify the reimbursements to retail pharmacies as related to AMPs Federal Upper Limits (FULs), expanding home infusion in Medicare to cover the supplies, equipment and services, and regarding expanding medication therapy management (MTM) services provided by pharmacists.
HR 2350 the Preserving Patient Access to Primary Care Act of 2009 all provisions; regarding increasing the number of primary care physicians and primary care providers, such as nurse practitioners and physician assistants, to improve patient access to primary care services.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Debbie |
Garza |
|
|
|
Susie |
Schulte |
|
|
|
Heather |
Smith |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |